cnbc semaglutide Novo Nordisk’s latest obesity drug trial disappoints, sending shares tumbling. CNBC’s Charlotte Reed investigates the setback. | International Expect Growth To Be Driven
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16











:format(jpg)/f.elconfidencial.com%2Foriginal%2Ff27%2Fb3a%2F460%2Ff27b3a460e92bcdc8635b6aa1b0eff12.jpg)













